Viridian Therapeutics, Inc.DE (VRDN) Stock
VRDN has an Alpha Score of 36 out of 100 (weak), computed on Nov 8, 2026 from 2 of 4 sub-scores. 4 of the hedge funds AlphaScala tracks reported VRDN in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Point72's at $43.04M. Company insiders reported 0 open-market buys and 2 sales on SEC Form 4 in the 90 days to Nov 10, 2026.
What is VRDN's Alpha Score?
How it works →Alpha Score of 36 reflects weak overall profile with moderate momentum, weak quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 8, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own VRDN?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Point72 Steve Cohen | 2.34M | $43.04M | +626% |
| D.E. Shaw David Shaw | 1.18M | $21.72M | -6% |
| Renaissance Technologies Jim Simons (founder) | 769K | $14.12M | +278% |
| Citadel Ken Griffin | 41K | $758.7K | -98% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Viridian Therapeutics, Inc.DE insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 19, 26 | Tousignant Jennifer | Chief Legal Officer | SELL | 4.2K | $103K |
| Aug 19, 26 | Tousignant Jennifer | Chief Legal Officer | SELL | 10.0K | $245K |
SEC Form 4 filings as of Nov 10, 2026
See cluster-buy signals across all tickers →What are VRDN's key statistics?
Key statistics as of Nov 8, 2026
How does VRDN's valuation compare with the Healthcare sector?
| Metric | VRDN | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -544.06% | 3.60% | 175 |
| Return on equity | -61.35% | 2.93% | 201 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 11, 2026). P/E excludes loss-making companies.
VRDN price chart
Powered by TradingViewWhat does Viridian Therapeutics, Inc.DE do?
Viridian Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing best-in-class medicines for patients with autoimmune and rare diseases, particularly thyroid eye disease (TED). The company leverages expertise in antibody discovery and protein engineering to create differentiated therapeutic candidates targeting validated disease mechanisms. Its lead programs include veligrotug, a humanized monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R) administered intravenously, currently in Phase 3 clinical trials (THRIVE and THRIVE-2) for active and chronic TED. Viridian is also advancing elegrobart (formerly VRDN-003), a next-generation subcutaneous IGF-1R antibody with half-life extension technology, in ongoing Phase 3 trials (REVEAL-1 and REVEAL-2) for TED. Additionally, the company develops an anti-thyroid-stimulating hormone receptor (TSHR) program for TED and Graves' disease, along with neonatal Fc receptor (FcRn) inhibitors such as VRDN-006 and VRDN-008 for multiple autoimmune conditions. Headquartered in Waltham, Massachusetts, and founded in 2006, Viridian Therapeutics plays a key role in addressing unmet needs in rare autoimmune therapies through innovative antibody-based treatments.